All In Biotech

Drug Trial Radar · NCT04045665

Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

Last checked: Nov 20, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 3,200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

3,200

Planned (sponsor's estimate)

Start

Dec 13, 2019

Primary completion

Aug 31, 2026

Study completion Aug 31, 2026

Sponsor

Lead sponsor
Icahn School of Medicine at Mount SinaiAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Heart, Lung, and Blood Institute (NHLBI); Vanderbilt University Medical Center
First posted
Aug 5, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery. All patients with a qualifying POAF event, who decline randomization, will be offered the option of enrollment in a parallel registry that captures their baseline risk profile and their treatment strategy in terms of anticoagulants or antiplatelets received. These patients will also be asked to fill out a brief decliner survey.

Conditions

  • Atrial Fibrillation
  • Stroke
  • Bleeding

Interventions

  • Antiplatelet-only strategyDrug

    Aspirin 75-325 mg once-daily or a P2Y12-inhibitor (clopidogrel or ticagrelor)

  • Oral Anticoagulant plus background antiplatelet therapyDrug

    OAC with vitamin K antagonist (VKA) with international normalized ratio (INR) target 2-3 or any approved direct oral anticoagulant OR apixaban, rivaroxaban, edoxaban or dabigatran) in addition to background antiplatelet therapy with aspirin 75-325mg once-daily or a P2Y12-inhibitor (clopidogrel or ticagrelor)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite of death, ischemic stroke, TIA, MI, systemic arterial thromboembolism or venous thromboembolism (DVT and/or PE)Time frame: up to 180 days after randomization
  2. Any BARC type 3 or 5Time frame: 90 days after randomization

Locations

106 sites in 5 countries. Site status is shown where the registry gives one.

  • CHI St. Vincent, Arkansas

    Little Rock, Arkansas · Recruiting

  • University of Southern California

    Los Angeles, California · Recruiting

  • Cedars-Sinai Medical Center

    Los Angeles, California · Recruiting

  • Stanford University

    Stanford, California · Recruiting

  • Medical Center of Aurora

    Aurora, Colorado · Active not recruiting

  • Western Connecticut Hospital Systems

    Danbury, Connecticut · Active not recruiting

  • Yale Medicine

    New Haven, Connecticut · Recruiting

  • MedStar Washington Hospital Center

    Washington D.C., District of Columbia · Recruiting

  • Emory University

    Atlanta, Georgia · Recruiting

  • Piedmont Healthcare Inc.

    Atlanta, Georgia · Recruiting

  • Lutheran Medical Center

    Fort Wayne, Indiana · Active not recruiting

  • Indiana University

    Indianapolis, Indiana · Active not recruiting

  • Ascension St. Vincent

    Indianapolis, Indiana · Active not recruiting

  • Ochsner Clinic

    New Orleans, Louisiana · Recruiting

  • Maine Medical Center

    Portland, Maine · Recruiting

  • University of Maryland

    Baltimore, Maryland · Recruiting

  • Johns Hopkins

    Baltimore, Maryland · Recruiting

  • Suburban Hospital

    Bethesda, Maryland · Active not recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Brigham and Women's Hospital

    Boston, Massachusetts · Recruiting

  • Boston Medical Center

    Boston, Massachusetts · Active not recruiting

  • Baystate Health

    Springfield, Massachusetts · Active not recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • Mid America Health Institute

    Kansas City, Missouri · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • Dartmouth-Hitchcock Medical Center

    Lebanon, New Hampshire · Recruiting

  • Jersey Shore University Medical Center

    Neptune City, New Jersey · Recruiting

  • Northwell Health System

    Great Neck, New York · Recruiting

  • The Mount Sinai Hospital

    New York, New York · Withdrawn

  • Columbia University Medical Center

    New York, New York · Recruiting

  • Montefiore Medical Center

    The Bronx, New York · Recruiting

  • Duke University

    Durham, North Carolina · Recruiting

  • East Carolina University

    Greenville, North Carolina · Recruiting

  • WakeMed

    Raleigh, North Carolina · Withdrawn

  • Cleveland Clinic Foundation

    Cleveland, Ohio · Recruiting

  • Ohio State University Medical Center

    Columbus, Ohio · Active not recruiting

  • Ascension St. John

    Tulsa, Oklahoma · Active not recruiting

  • University of Pittsburgh Medical Center

    Hermitage, Pennsylvania · Withdrawn

  • University of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

Showing 40 of 106 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.